Lymphoma Research Foundation, New York, NY, USA.
Mayo Clinic Foundation, Rochester, MN, USA.
Blood Cancer J. 2021 Apr 5;11(4):68. doi: 10.1038/s41408-021-00456-w.
Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and rituximab, selinexor, and tafasitamab plus lenalidomide. Three CAR-T cell products are currently approved by the FDA, with others in clinical trials. Additional agents in development include bispecific antibodies and antibody drug conjugates. Combinations of targeted therapies should lead to further improvement in the outcome of patients with B-cell malignancies.
对于弥漫性大 B 细胞淋巴瘤 (DLBCL) 和其他 B 细胞恶性肿瘤患者，新的、更有效和非细胞毒性的治疗方法是未满足的需求。最近批准的药物包括泊洛妥珠单抗联合苯达莫司汀和利妥昔单抗、塞利尼索、以及塔法昔单抗联合来那度胺。三种 CAR-T 细胞产品目前已获 FDA 批准，其他产品正在临床试验中。正在开发的其他药物包括双特异性抗体和抗体药物偶联物。靶向治疗的联合应用应能进一步改善 B 细胞恶性肿瘤患者的预后。
Zotero 插件
